Should hydralazine be given on dialysis days, and should it be administered after the dialysis session to avoid intradialytic hypotension?

Should Hydralazine Be Given on Dialysis Days?

Yes, hydralazine can be given on dialysis days, and when used, it should be administered after the dialysis session is complete to minimize the risk of intradialytic hypotension.

Rationale and Key Considerations

Timing of Administration

The primary concern with hydralazine on dialysis days is its potential to cause or worsen intradialytic hypotension. Hydralazine causes blood pressure to decrease within 10-30 minutes of administration, with effects lasting 2-4 hours 1, 2. This unpredictable response and prolonged duration make it problematic if given before or during dialysis.

The safest approach is to administer hydralazine after dialysis is complete, similar to the principle established for other medications in dialysis patients 3. This timing:

• Avoids compounding the hypotensive effects of ultrafiltration during dialysis
• Prevents premature dialysis termination due to symptomatic hypotension
• Ensures adequate dialysis dose delivery
• Reduces the risk of end-organ hypoperfusion during the vulnerable intradialytic period

Understanding Intradialytic Hypotension Risk

Intradialytic hypotension is a major complication affecting dialysis adequacy and patient outcomes 4. The NKF-K/DOQI guidelines emphasize that 15% of premature dialysis terminations are due to symptomatic hypotension 4. When hypotension occurs, healthcare teams often reduce blood flow and ultrafiltration rates, compromising the delivered dialysis dose.

Hydralazine is particularly problematic because:

• It has an unpredictable blood pressure response 1, 2
• Its effects last 2-4 hours, potentially spanning an entire dialysis session
• It causes postural hypotension 5
• The FDA label specifically warns about its use with other antihypertensive drugs causing profound hypotensive episodes 5

Alternative Strategies Before Adding Hydralazine

Before relying on hydralazine for blood pressure control in dialysis patients, prioritize these evidence-based interventions 4:

1. Volume management: Reassess target dry weight and avoid excessive ultrafiltration
2. Sodium restriction: Limit interdialytic sodium intake to reduce fluid gains
3. Dialysis prescription modifications:
   • Slow the ultrafiltration rate
   • Increase dialysate sodium concentration
   • Reduce dialysate temperature
4. First-line antihypertensive agents: Consider ACE inhibitors, ARBs, or calcium channel blockers that can be dosed once daily at night 6, 7

Medication Selection Considerations

If antihypertensive therapy is needed, hydralazine is not a first-line choice for chronic blood pressure management in dialysis patients 6, 7. The 2020 KDIGO conference on blood pressure management in dialysis recommends:

• ACE inhibitors/ARBs as first-line agents
• Calcium channel blockers as alternatives
• Consideration of medication dialyzability and intradialytic blood pressure patterns 6

Hydralazine's role is primarily:

• As a component of combination therapy (hydralazine-isosorbide dinitrate) for heart failure in specific populations 8
• For acute hypertensive emergencies (IV formulation) 1, 2
• When other agents are contraindicated or not tolerated

Evidence from Dialysis-Specific Studies

Recent research provides mixed signals about hydralazine-isosorbide dinitrate (H-ISDN) in dialysis patients:

• A 2020 pilot trial found H-ISDN was tolerable in maintenance hemodialysis patients, with fewer intradialytic hypotension events compared to placebo (0.47 vs 1.83 events/patient-year, P=0.04) 9. However, gastrointestinal side effects were more common.

• A 2022 retrospective USRDS analysis showed H-ISDN use was associated with lower all-cause mortality (HR 0.48) and cardiovascular death (HR 0.62) 10, though this observational data has inherent limitations.

Practical Algorithm for Hydralazine Use on Dialysis Days

If hydralazine must be used:

1. Assess intradialytic hypotension risk: Review recent dialysis sessions for hypotensive episodes
2. Optimize volume status first: Ensure target dry weight is appropriate
3. Time administration post-dialysis: Give hydralazine only after dialysis session completion
4. Monitor closely: Check blood pressure 30 minutes and 2 hours post-administration initially
5. Consider non-dialysis day dosing: If possible, schedule doses on non-dialysis days to avoid any interaction with the dialysis procedure
6. Avoid pre-dialysis dosing: Never give hydralazine the morning of or immediately before dialysis

Common Pitfalls to Avoid

• Do not routinely withhold all antihypertensives before dialysis 11. This practice lacks strong evidence and may worsen interdialytic blood pressure control
• Do not use hydralazine as monotherapy for chronic hypertension in dialysis patients when better-studied alternatives exist
• Do not ignore volume status: Many dialysis patients have hypertension primarily due to volume overload 12, which requires ultrafiltration adjustment rather than additional vasodilators
• Do not forget pyridoxine supplementation: Hydralazine has an antipyridoxine effect; consider supplementation with chronic use 5

Monitoring Requirements

The FDA label mandates specific monitoring for hydralazine 5:

• Complete blood counts periodically
• Antinuclear antibody titers (risk of drug-induced lupus)
• Blood pressure monitoring for excessive hypotension
• Assessment for peripheral neuritis symptoms

In dialysis patients, add monitoring for:

• Intradialytic blood pressure patterns
• Adequacy of dialysis delivery (Kt/V)
• Symptoms during and after dialysis sessions